The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion
Abstract Bromodomain and extraterminal domain (BET) proteins have emerged as therapeutic targets in multiple cancers, including the most common primary adult brain tumor glioblastoma (GBM). Although several BET inhibitors have entered clinical trials, few are brain penetrant. We have generated UM-00...
Saved in:
Main Authors: | Anna M. Jermakowicz, Matthew J. Rybin, Robert K. Suter, Jann N. Sarkaria, Zane Zeier, Yangbo Feng, Nagi G. Ayad |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/42bc0a0c7a934a7485fd2a2ac6e81440 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug and disease signature integration identifies synergistic combinations in glioblastoma
by: Vasileios Stathias, et al.
Published: (2018) -
A Pruning Optimized Fast Learn++NSE Algorithm
by: Yong Chen, et al.
Published: (2021) -
BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4
by: Hae In Choi, et al.
Published: (2021) -
“Betting on nature” or “betting on others”: anti-coordination induces uniquely high levels of entropy
by: Gabriele Chierchia, et al.
Published: (2018) -
Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity
by: David Estoppey, et al.
Published: (2021)